Yesterday, it was announced that Johnson and Johnson (J&J) had sought a preliminary injunction against Samsung Bioepis to prevent sales of a planned private-label version of Pyzchiva with an undisclosed pharmacy benefit manager (PBM). J&J claimed that the licensing arrangement signed in 2023 with Samsung did not permit sublicensing, as it was referred to in … Continue reading What the J&J Suit Against Samsung Bioepis Tells Us